User login
Key clinical point: After adjustment for hyperlipidemia, the risk of developing rheumatoid arthritis (RA) was not higher among statin users than nonusers.
Major finding: After adjusting for hyperlipidemia, the risk of developing RA was not higher among former users of statins (adjusted odds ratio [aOR] 1.03; 95% CI 0.96-1.10) and was slightly lower among current users (aOR 0.87; 95% CI 0.81-0.93) than nonusers.
Study details: This was a nationwide case-control study of 16,363 patients with RA and a similar number of matched control participants.
Disclosures: The National Institutes of Health, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, and the National Institute on Aging funded this work. None of the authors declared any conflict of interest.
Source: Peterson MN et al. Arthritis Res Ther. 2021 (Sep 18):23:244. doi: 10.1186/s13075-021-02617-5.
Key clinical point: After adjustment for hyperlipidemia, the risk of developing rheumatoid arthritis (RA) was not higher among statin users than nonusers.
Major finding: After adjusting for hyperlipidemia, the risk of developing RA was not higher among former users of statins (adjusted odds ratio [aOR] 1.03; 95% CI 0.96-1.10) and was slightly lower among current users (aOR 0.87; 95% CI 0.81-0.93) than nonusers.
Study details: This was a nationwide case-control study of 16,363 patients with RA and a similar number of matched control participants.
Disclosures: The National Institutes of Health, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, and the National Institute on Aging funded this work. None of the authors declared any conflict of interest.
Source: Peterson MN et al. Arthritis Res Ther. 2021 (Sep 18):23:244. doi: 10.1186/s13075-021-02617-5.
Key clinical point: After adjustment for hyperlipidemia, the risk of developing rheumatoid arthritis (RA) was not higher among statin users than nonusers.
Major finding: After adjusting for hyperlipidemia, the risk of developing RA was not higher among former users of statins (adjusted odds ratio [aOR] 1.03; 95% CI 0.96-1.10) and was slightly lower among current users (aOR 0.87; 95% CI 0.81-0.93) than nonusers.
Study details: This was a nationwide case-control study of 16,363 patients with RA and a similar number of matched control participants.
Disclosures: The National Institutes of Health, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, and the National Institute on Aging funded this work. None of the authors declared any conflict of interest.
Source: Peterson MN et al. Arthritis Res Ther. 2021 (Sep 18):23:244. doi: 10.1186/s13075-021-02617-5.